Intratumor Heterogeneity of MYO18A and FBXW7 Variants Impact the Clinical Outcome of Stage III Colorectal Cancer

Many studies failed to demonstrate benefit from the addition of targeted agents to current standard adjuvant FOLFOX chemotherapy in stage III colorectal cancer (CRC) patients. Intratumor heterogeneity may foster the resistant subclones and leads to cancer recurrence. Here, we built a cancer evolutio...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Peng-Chan, Yeh, Yu-Min, Lin, Bo-Wen, Lin, Shao-Chieh, Chan, Ren-Hao, Chen, Po-Chuan, Shen, Meng-Ru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658598/
https://www.ncbi.nlm.nih.gov/pubmed/33194745
http://dx.doi.org/10.3389/fonc.2020.588557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658598/
https://www.ncbi.nlm.nih.gov/pubmed/33194745
http://dx.doi.org/10.3389/fonc.2020.588557

Ejemplares similares